Skip to content

Study · Animal study (in vivo) · mouse · 2014

6 results

Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies.

Toyama S, Shimoyama N, Ishida Y, Koyasu T, Szeto HH, Shimoyama M

Anesthesiology1 Feb 2014Cited by 47 (Europe PMC)

PMID24064792 (opens in a new tab)DOI10.1097/01.anes.0000435634.34709.65 (opens in a new tab)PepBankPUB-24064792
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice given repeated oxaliplatin, concomitant SS‑31 attenuated cold hypersensitivity.

    In plain wordsIn mice given oxaliplatin repeatedly, SS‑31 given at the same time reduced the pain response to cold.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCold hypersensitivity, SS-31 with oxaliplatin
    Study

    mousen: not reported in source

    Oxaliplatin-induced neuropathy
    Comparator
    Oxaliplatin without SS-31
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concomitant SS-31 administration with repeated oxaliplatin administration attenuated both cold and mechanical hypersensitivity.
    2 context sentences
    Summary · context
    Neuropathy was induced by single or repeated injections of oxaliplatin.
    Summary · context
    SS-31 was administered concomitantly or after oxaliplatin injections.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice given repeated oxaliplatin, concomitant SS‑31 attenuated mechanical hypersensitivity.

    In plain wordsIn mice given oxaliplatin repeatedly, SS‑31 given at the same time reduced the pain response to touch.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMechanical hypersensitivity, SS-31 with oxaliplatin
    Study

    mousen: not reported in source

    Oxaliplatin-induced neuropathy
    Comparator
    Oxaliplatin without SS-31
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concomitant SS-31 administration with repeated oxaliplatin administration attenuated both cold and mechanical hypersensitivity.
    2 context sentences
    Summary · context
    Neuropathy was induced by single or repeated injections of oxaliplatin.
    Summary · context
    SS-31 was administered concomitantly or after oxaliplatin injections.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice given repeated oxaliplatin, concomitant SS‑31 attenuated the decrease in intraepidermal nerve fibers.

    In plain wordsIn mice given oxaliplatin repeatedly, SS‑31 reduced the loss of nerve fibers in the skin.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseIntraepidermal nerve fiber density
    Study

    mousen: not reported in source

    Oxaliplatin-induced neuropathy
    Comparator
    Oxaliplatin without SS-31
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Decrease in intraepidermal nerve fibers and increase in dorsal root ganglion-reactive oxygen/nitrogen species were also attenuated.
    2 context sentences
    Summary · context
    Neuropathy was induced by single or repeated injections of oxaliplatin.
    Summary · context
    SS-31 was administered concomitantly or after oxaliplatin injections.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice given repeated oxaliplatin, concomitant SS‑31 attenuated the increase in dorsal root ganglion reactive oxygen/nitrogen species.

    In plain wordsIn mice given oxaliplatin repeatedly, SS‑31 reduced the rise in reactive oxygen species in nerve cell clusters.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseDorsal root ganglion reactive oxygen/nitrogen species
    Study

    mousen: not reported in source

    Oxaliplatin-induced neuropathy
    Comparator
    Oxaliplatin without SS-31
    Outcome group
    Oxidative stress · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Decrease in intraepidermal nerve fibers and increase in dorsal root ganglion-reactive oxygen/nitrogen species were also attenuated.
    2 context sentences
    Summary · context
    Neuropathy was induced by single or repeated injections of oxaliplatin.
    Summary · context
    SS-31 was administered concomitantly or after oxaliplatin injections.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with established oxaliplatin neuropathy, acute SS‑31 administration reversed cold hypersensitivity.

    In plain wordsIn mice with oxaliplatin nerve damage already present, SS‑31 reversed the pain response to cold.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseEstablished cold hypersensitivity, SS-31 after oxaliplatin
    Study

    mousen: not reported in source

    Oxaliplatin-induced neuropathy
    Comparator
    Oxaliplatin without SS-31
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute SS-31 administration after symptoms were established reversed only cold hypersensitivity.
    2 context sentences
    Summary · context
    Neuropathy was induced by single or repeated injections of oxaliplatin.
    Summary · context
    SS-31 was administered concomitantly or after oxaliplatin injections.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with established oxaliplatin neuropathy, acute SS‑31 administration did not reverse mechanical hypersensitivity.

    In plain wordsIn mice with oxaliplatin nerve damage already present, SS‑31 did not reverse the pain response to touch.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeEstablished mechanical hypersensitivity, SS-31 after oxaliplatin
    Study

    mousen: not reported in source

    Oxaliplatin-induced neuropathy
    Comparator
    Oxaliplatin without SS-31
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute SS-31 administration after symptoms were established reversed only cold hypersensitivity.
    2 context sentences
    Summary · context
    Neuropathy was induced by single or repeated injections of oxaliplatin.
    Summary · context
    SS-31 was administered concomitantly or after oxaliplatin injections.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.